HC Wainwright Issues Positive Estimate for MRKR Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for Marker Therapeutics in a research report issued on Thursday, August 20th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.16) for the quarter, up from their prior forecast of ($0.25). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Marker Therapeutics’ FY2026 earnings at ($0.63) EPS, Q1 2027 earnings at ($0.22) EPS, Q2 2027 earnings at ($0.25) EPS, Q3 2027 earnings at ($0.21) EPS, Q4 2027 earnings at ($0.23) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.85) EPS, FY2029 earnings at ($0.95) EPS and FY2030 earnings at ($1.02) EPS.

Separately, Weiss Ratings upgraded shares of Marker Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $10.00.

Marker Therapeutics Trading Up 7.9%

Shares of NASDAQ:MRKR opened at $1.50 on Monday. The stock has a market cap of $25.01 million, a PE ratio of -3.66 and a beta of 1.50. The stock’s fifty day simple moving average is $1.31 and its two-hundred day simple moving average is $1.40. Marker Therapeutics has a 1-year low of $0.81 and a 1-year high of $2.46.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.16. Marker Therapeutics had a negative return on equity of 56.96% and a negative net margin of 343.03%.

Institutional Trading of Marker Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its stake in Marker Therapeutics by 41.8% in the first quarter. Renaissance Technologies LLC now owns 175,294 shares of the company’s stock valued at $228,000 after acquiring an additional 51,644 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Marker Therapeutics during the 4th quarter worth approximately $222,000. Geode Capital Management LLC increased its stake in shares of Marker Therapeutics by 35.3% during the 4th quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock worth $194,000 after purchasing an additional 34,028 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of Marker Therapeutics by 16.5% in the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after purchasing an additional 13,340 shares during the period. Finally, LPL Financial LLC raised its holdings in shares of Marker Therapeutics by 41.7% in the 4th quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after purchasing an additional 24,500 shares during the period. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.